drugset / Trial / NCT02106585

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

NCT02106585 ↗

Phase 1 Completed 94 enrolled Akros Pharma Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and PK (Pharmacokinetics) of single oral doses of JTT-251 in healthy and type 2 diabetes mellitus subjects and to evaluate the effect of food on the PK of JTT-251 in healthy subjects.

Timeline

Start
2014-03
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject JTT-251 Small molecule — Oral

Indications